FDA Submission Update for Dalfampridine by Accord Healthcare
The submission of an ANDA for Dalfampridine by Accord Healthcare signals the potential entry of a generic competitor into the market. This could lead to significant pricing pressures and market share erosion for current brand holders, necessitating strategic responses.
Asset
Dalfampridine
Indication
Neurology / Multiple Sclerosis
Status
Approved
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The submission of an ANDA for Dalfampridine by Accord Healthcare signals the potential entry of a generic competitor into the market. This could lead to significant pricing pressures and market share erosion for current brand holders, necessitating strategic responses.
Why it matters
The submission of an ANDA for Dalfampridine by Accord Healthcare signals the potential entry of a generic competitor into the market. This could lead to significant pricing pressures and market share erosion for current brand holders, necessitating strategic responses.
What changed
Regulatory Approval
Analysis
Accord Healthcare has submitted an Abbreviated New Drug Application (ANDA) for Dalfampridine, currently under standard review.
The submission of an ANDA for Dalfampridine by Accord Healthcare signals the potential entry of a generic competitor into the market. This could lead to significant pricing pressures and market share erosion for current brand holders, necessitating strategic responses.
Monitor the FDA's review timeline and any subsequent approval announcements for the ANDA.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.